Primary Hyperoxaluria Type 1 (PH1)
Lumasiran for Advanced Primary Hyperoxaluria Type 1: Phase 3 ILLUMINATE-C Trial
American Journal of Kidney Diseases
Acute Hepatic Porphyria (AHP)
Patient Perspective on Acute Hepatic Porphyria with Sporadic Attacks: A Chronic Disease with Substantial Health-Related Quality of Life Impacts
Advances in Therapy
Transthyretin Amyloidosis (ATTR)
Patisiran treatment in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy after liver transplantation
American Journal of Transplantation
Primary Hyperoxaluria Type 1 (PH1)
Randomized Clinical Trial on the Long-Term Efficacy and Safety of Lumasiran in Patients With Primary Hyperoxaluria Type 1
Kidney International Reports
Primary Hyperoxaluria Type 1 (PH1)
Phase 3 trial of lumasiran for primary hyperoxaluria type 1: A new RNAi therapeutic in infants and young children
Genetics in Medicine
Primary Hyperoxaluria Type 1 (PH1)
Primary Hyperoxaluria Type 1 Disease Manifestations and Healthcare Utilization: A Multi-Country, Online, Chart Review Study
Frontiers in Medicine
Acute Hepatic Porphyria (AHP)
A Drug-Drug Interaction Study Evaluating the Effect of Givosiran, a Small Interfering Ribonucleic Acid, on Cytochrome P450 Activity in the Liver
Clinical Pharmacology and Therapeutics
Transthyretin Amyloidosis (ATTR)
Presence of the V122I Variant of Hereditary Transthyretin-Mediated Amyloidosis Among Self-Reported White Individuals in a Sponsored Genetic Testing Program
Circulation: Genomic and Precision Medicine
Primary Hyperoxaluria Type 1 (PH1)
Phase 1/2 Study of Lumasiran for Treatment of Primary Hyperoxaluria Type 1: A Placebo-Controlled Randomized Clinical Trial
Clinical Journal of the American Society of Nephrology
Primary Hyperoxaluria Type 1 (PH1)
Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1
New England Journal of Medicine
